Selected research
Industry Growth & Trends
Global Peptide-based Drug Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Peptide-based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Peptide-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Peptide-based Drug market include Takeda, Teva, Sanofi, J & J, Novartis, Merck, Eli Lilly, AbbVie and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Peptide-based Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Peptide-based Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Peptide-based Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Peptide-based Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Peptide-based Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Peptide-based Drug Market by Company
Takeda
Teva
Sanofi
J & J
Novartis
Merck
Eli Lilly
AbbVie
AstraZeneca
The Medicines
Novo Nordisk
Ipsen
Ferring
Peptide-based Drug Segment by Type
Injection
Oral
Other
Peptide-based Drug Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
Peptide-based Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-based Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Peptide-based Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral
- Other
Applications
- Cancer
- Metabolic Disorders
- Central Nervous System
- Other
Companies covered
- Takeda
- Teva
- Sanofi
- J & J
- Novartis
- Merck
- Eli Lilly
- AbbVie
- AstraZeneca
- The Medicines
- Novo Nordisk
- Ipsen
- Ferring
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Peptide-based Drug Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Peptide-based Drug Market Size by Region (2021-2032)
- 1.4.1 Global Peptide-based Drug Market Size by Region (2021-2026)
- 1.4.2 Global Peptide-based Drug Market Size by Region (2027-2032)
- 1.5 Key Regions Peptide-based Drug Market Size (2021-2032)
- 1.5.1 North America Peptide-based Drug Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Peptide-based Drug Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Peptide-based Drug Market Size Growth Rate (2021-2032)
- 1.5.4 South America Peptide-based Drug Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Peptide-based Drug Market Size Growth Rate (2021-2032)
2 Peptide-based Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 Injection
- 2.1.2 Oral
- 2.1.3 Other
- 2.2 Global Peptide-based Drug Market Size by Type
- 2.2.1 Global Peptide-based Drug Market Size Overview by Type (2021-2032)
- 2.2.2 Global Peptide-based Drug Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Peptide-based Drug Market Size Forecasted by Type (2027-2032)
- 2.3 Global Peptide-based Drug Market Size by Regions
- 2.3.1 North America Peptide-based Drug Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Peptide-based Drug Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Peptide-based Drug Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Peptide-based Drug Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Peptide-based Drug Market Size Breakdown by Type (2021-2026)
3 Peptide-based Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Cancer
- 3.1.2 Metabolic Disorders
- 3.1.3 Central Nervous System
- 3.1.4 Other
- 3.2 Global Peptide-based Drug Market Size by Application
- 3.2.1 Global Peptide-based Drug Market Size Overview by Application (2021-2032)
- 3.2.2 Global Peptide-based Drug Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Peptide-based Drug Market Size Forecasted by Application (2027-2032)
- 3.3 Global Peptide-based Drug Market Size by Regions
- 3.3.1 North America Peptide-based Drug Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Peptide-based Drug Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Peptide-based Drug Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Peptide-based Drug Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Peptide-based Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Peptide-based Drug Industry Trends
- 4.2 Peptide-based Drug Industry Drivers
- 4.3 Peptide-based Drug Industry Opportunities and Challenges
- 4.4 Peptide-based Drug Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Peptide-based Drug Revenue (2021-2026)
- 5.2 Global Peptide-based Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Peptide-based Drug Key Company Headquarters & Area Served
- 5.4 Global Peptide-based Drug Company, Product Type & Application
- 5.5 Global Peptide-based Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Peptide-based Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Peptide-based Drug Players Market Share by Revenue in 2025
- 5.6.3 2025 Peptide-based Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Takeda
- 6.1.1 Takeda Company Information
- 6.1.2 Takeda Business Overview
- 6.1.3 Takeda Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Takeda Peptide-based Drug Product Portfolio
- 6.1.5 Takeda Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Teva Peptide-based Drug Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sanofi Peptide-based Drug Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 J & J
- 6.4.1 J & J Company Information
- 6.4.2 J & J Business Overview
- 6.4.3 J & J Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 J & J Peptide-based Drug Product Portfolio
- 6.4.5 J & J Recent Developments
- 6.5 Novartis
- 6.5.1 Novartis Company Information
- 6.5.2 Novartis Business Overview
- 6.5.3 Novartis Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Novartis Peptide-based Drug Product Portfolio
- 6.5.5 Novartis Recent Developments
- 6.6 Merck
- 6.6.1 Merck Company Information
- 6.6.2 Merck Business Overview
- 6.6.3 Merck Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Merck Peptide-based Drug Product Portfolio
- 6.6.5 Merck Recent Developments
- 6.7 Eli Lilly
- 6.7.1 Eli Lilly Company Information
- 6.7.2 Eli Lilly Business Overview
- 6.7.3 Eli Lilly Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Eli Lilly Peptide-based Drug Product Portfolio
- 6.7.5 Eli Lilly Recent Developments
- 6.8 AbbVie
- 6.8.1 AbbVie Company Information
- 6.8.2 AbbVie Business Overview
- 6.8.3 AbbVie Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 AbbVie Peptide-based Drug Product Portfolio
- 6.8.5 AbbVie Recent Developments
- 6.9 AstraZeneca
- 6.9.1 AstraZeneca Company Information
- 6.9.2 AstraZeneca Business Overview
- 6.9.3 AstraZeneca Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 AstraZeneca Peptide-based Drug Product Portfolio
- 6.9.5 AstraZeneca Recent Developments
- 6.10 The Medicines
- 6.10.1 The Medicines Company Information
- 6.10.2 The Medicines Business Overview
- 6.10.3 The Medicines Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 The Medicines Peptide-based Drug Product Portfolio
- 6.10.5 The Medicines Recent Developments
- 6.11 Novo Nordisk
- 6.11.1 Novo Nordisk Company Information
- 6.11.2 Novo Nordisk Business Overview
- 6.11.3 Novo Nordisk Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Novo Nordisk Peptide-based Drug Product Portfolio
- 6.11.5 Novo Nordisk Recent Developments
- 6.12 Ipsen
- 6.12.1 Ipsen Company Information
- 6.12.2 Ipsen Business Overview
- 6.12.3 Ipsen Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Ipsen Peptide-based Drug Product Portfolio
- 6.12.5 Ipsen Recent Developments
- 6.13 Ferring
- 6.13.1 Ferring Company Information
- 6.13.2 Ferring Business Overview
- 6.13.3 Ferring Peptide-based Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Ferring Peptide-based Drug Product Portfolio
- 6.13.5 Ferring Recent Developments
7 North America
- 7.1 North America Peptide-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Peptide-based Drug Market Size by Country (2021-2026)
- 7.3 North America Peptide-based Drug Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Peptide-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Peptide-based Drug Market Size by Country (2021-2026)
- 8.3 Europe Peptide-based Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Peptide-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Peptide-based Drug Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Peptide-based Drug Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Peptide-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Peptide-based Drug Market Size by Country (2021-2026)
- 10.3 South America Peptide-based Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Peptide-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Peptide-based Drug Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Peptide-based Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst